What does Arrowhead Pharmaceuticals do?

Arrowhead Pharmaceuticals develops experimental medicines that use RNA interference (RNAi) to switch off specific genes that drive disease. Its drug candidates target conditions such as high blood fats, liver and metabolic disorders, obesity-related pathways, complement-driven immune diseases, and neurological conditions. Most of its programs are still in clinical trials, and its most advanced drugs are in late-stage Phase 3 studies.

What is Arrowhead Pharmaceuticals's fair value?

On an owner-earnings DCF, Arrowhead Pharmaceuticals's most-likely fair value is about $17, versus a recent price near $63. A margin-of-safety estimate, not a price target. Analysis, not advice.

Healthcare · Biotechnology · ARWR

What Arrowhead Pharmaceuticals Does & How It Makes Money (ARWR)

Updated October 2026 · reflects Arrowhead Pharmaceuticals's latest reported financials

Biotech developing RNA interference (RNAi) medicines for hard-to-treat diseases. Arrowhead earns revenue mainly through collaboration and license agreements with large drugmakers such as GSK, Takeda, Amgen and Sarepta, which can include upfront and milestone payments.

Arrowhead Pharmaceuticals's story, moat and numbers — in a 3-minute visual book.

Explore Arrowhead Pharmaceuticals on TacticScale →

How Arrowhead Pharmaceuticals makes money

Arrowhead earns revenue mainly through collaboration and license agreements with large drugmakers such as GSK, Takeda, Amgen and Sarepta, which can include upfront and milestone payments. Longer term it aims to earn product sales if its pipeline drugs are approved.

What Arrowhead Pharmaceuticals does

Arrowhead Pharmaceuticals, founded in 2003 and based in Pasadena, California, is a clinical-stage biotech built around RNAi therapeutics, which are drugs that silence specific disease-causing genes. Its most advanced candidates are plozasiran, which lowers apolipoprotein C-III, and zodasiran, which lowers ANGPTL3. Both target blood lipids and are in Phase 3 trials. Behind those two, the company has a broad early- and mid-stage pipeline. It includes ARO-INHBE and ARO-ALK7 for metabolic and fat-tissue pathways, ARO-PNPLA3 for the liver, ARO-C3 and ARO-CFB for complement-mediated diseases, ARO-RAGE, the dual-function ARO-DIMER-PA, and ARO-MAPT for neurology. Partnerships with GSK, Takeda, Amgen and Sarepta provide external validation and funding.

Products & services

Plozasiran (APOC3, Phase 3)
Zodasiran (ANGPTL3, Phase 3)
ARO-INHBE
ARO-ALK7
ARO-C3
ARO-MAPT

What is Arrowhead Pharmaceuticals worth?

On an owner-earnings DCF, Arrowhead Pharmaceuticals's most-likely value is about $17 versus a recent price near $63 (72% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$4) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.

Verdict: Fairly priced — no edge

Owner-earnings fair value · recent price ≈ $63

Fair value (most likely)

$17

Range

$7–$52

No-growth floor

Price

~$63

Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.

Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →

Sector Healthcare Industry Biotechnology HQ United States Ticker ARWR Official site

Related companies

Arcus Biosciences (RCUS) · Vir Biotechnology (VIR) · Amgen (AMGN) · Aurisco Pharmaceutical (605116.SS) · Roivant Sciences (ROIV)

Understand Arrowhead Pharmaceuticals in 3 minutes →